Bing

SEARCH HISTORY

NEW YORK (AP) — Teva has offered to buy Mylan for about $40.1 billion in cash and stock in a deal that would create a powerhouse of generic drug development. FILE - In this Oct. 16, 2013 file photo, trucks run past Teva Pharmaceutical Logistic Center in ...
Oklahoma News · 4/21/2015
Mylan rejected Teva's $82-a-share cash and stock bid on Monday. Mylan changed hands recently at $72.26, off 3 percent. Teva's Chief Executive Erez Vigodman reiterated his company's $40 billion offer for Mylan in a letter Wednesday, which took Mylan to …
Benzinga · 4/30/2015
Mylan’s cash-and-stock offer comes at a premium of 24 percent to the latest closing price for Perrigo shares, according to the Associated Press. The combined company will be a juggernaut in generic and specialty drugs as well as over-the-counter …
ETF Trends Setting The Pace · 4/8/2015
More from Bing News
Teva’s proposal would provide Mylan stockholders with consideration representing a 37.7% premium to the stock price of Mylan on April 7, 2015, which is the last day of trading prior to Mylan’s press release regarding its unsolicited proposal for ...
drugstorenews.com · 4/21/2015
In late April, Mylan NV rejected the cash-and-stock buyout bid from Teva, saying then that the deal undervalued the company. Both Mylan and Israeli based Teva Pharmaceutical Industries Ltd. are looking to consolidate in an increasingly competitive generic ...
ABC News · 6/8/2015
Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
Modern Healthcare · 4/22/2015
Abbott is the largest holder of Mylan after swapping its established-markets drug business for Mylan stock in February. Since then, Mylan shares have surged more than 20 percent as the drugmaker pursues Perrigo Co. and fends off advances from Teva ...
Crain's Chicago Business · 5/8/2015
That amounts to $222.12 a share based on Mylan’s closing price on Thursday—10% above the price of Perrigo’s stock the same day. Perrigo rejected the new offer, arguing it’s not as high as it seems because Mylan’s stock has been inflated by Teva ...
Live Mint · 4/25/2015
Teva’s offer included cash and stock deals which created a buzz internationally and among business journalists Tuesday morning. In the same release Coury added, “Of course, should any party make an actual offer to acquire Mylan, the board would ...
Metro News · 4/21/2015
Today, Teva responded to Mylan’s rejection letter with a press release reaffirming its commitment to the transaction. Read the release here: Teva Reiterates Commitment to Cash-and-Stock Acquisition of Mylan for $82.00 Per Share. Erez Vigodman ...
Market Realist · 4/28/2015

Mylan

Company
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters …
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, Hertfordshire in the United Kingdom. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan now has approximately 22,000 employees, more than 1,000 separate products, and serves customers in more than 150 countries and territories. Mylan has a global manufacturing output of more than 45 billion doses.
Data from: Wikipedia · Freebase